Arsenic trioxide induces multiple myeloma cell apoptosis via disruption of mitochondrial transmembrane potentials and activation of caspase-3

Chinese Medical Journal

Volumn 114, Issue 1, 2001, Pages 19-24

  Jia, Peimin ^a   Chen, Guoqiang ^a   Huang, Xiaojun ^b   Cai, Xun ^a   Yang, Jie ^c   Wang, Long ^a   Zhou, Yuhong ^b   Shen, Yulei ^a   Zhou, Li ^a   Yu, Yun ^a   Chen, Saijuan ^a   Zhang, Xueguang ^d   Wang, Zhenyi ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d SUZHOU UNIVERSITY   (China)

Author keywords

Apoptosis; Arsenic trioxide; Mitochondrial transmembrane potentials; Multiple myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BUTHIONINE SULFOXIMINE; CASP3 PROTEIN, HUMAN; CASPASE; CASPASE 3; ORGANOARSENIC DERIVATIVE; OXIDE; RETINOIC ACID;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL MEMBRANE POTENTIAL; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; HUMAN; MITOCHONDRION; MULTIPLE MYELOMA; PATHOLOGY; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BUTHIONINE SULFOXIMINE; CASPASE 3; CASPASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HUMANS; MEMBRANE POTENTIALS; MITOCHONDRIA; MULTIPLE MYELOMA; OXIDES; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0035240425     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Greipp PR, Witzig T. Biology and treatment of myeloma. Curr Opin Oncol 1996;8:20-27.
2. Attal M, Harousseau JL. Standard therapy versus autologous transplantation in multiple myeloma. Hematol Oncol Clin North Am 1997;11:133-141.
3. + cells. Br J Haematol 1995;90:625-632.
4. Goldmacher VS, Bourret LA, Levine BA, et al. Anti-CD38-blocked recin: an immunotoxin for the treatment of multiple myeloma. Blood 1994;84:3017-3025.
5. Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of anti-IL-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995;86:685-691.
6. Petterson M, Jernberg-Wiklund H, larsson LG, et al. Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood 1992;79:495-503.
7. Tu Y, Xu F, Liu J, et al. Expression of bel-XL in multiple myeloma plasma cells. Blood 1995;86:62a.
8. Landowski TH, Qu N, Buyuksal I, et al. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997;90:4266-4270.
9. 3) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients. Blood 1997;89:3354-3360.
10. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-1348.
11. 3 induces NB4 cell apoptosis with down-regulation of Bcl-2 expression and alteration of PML-RARa/PML protein localization. Blood 1996;88:1052-1062.
12. 3 exerts dual effects on APL Cells. Blood 1997;89:3345-3353.
13. Akao Y, Mizoguchi H, Kojima S, et al. Arsenic induces apoptosis in B-cell leukaemic cell lines: activation of caspases and down-regulation of Bcl-2 protein. Br J Haematol 1998;102:1055-1060.
14. Zhang W, Ohnishi K, Shigeno K, et al. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998;12:1383-1391.
15. Ishitsuka K, Hanada S, Suzuki S, et al. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. Br J Haematol 1998;103:721-728.
16. Zhu XH, Shen YL, Jing YK, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999;91:772-778.
17. Rousselot P, Labaume S, Marolleau JP, et al. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 1999;59:1041-1048.
18. Kroemer G, de The H. Arsenic trioxide, a novel mitochondriotoxic anticancer agent? J Natl Cancer Inst 1999;91:743-745.
19. Chen YC, Lin-Shiau SY, Lin JK. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol 1998;177:324-333.
20. Larochette N, Decaudin D, Jacotot E, et al. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res 1999;249:413-421.
21. Sidell N, Taga T, Hirano T, et al. Retinioc acid induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. J Immunol 1991;146:3809-3814.
22. Ogata A, Nishimoto N, Shima Y, et al. Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interferences with IL-6 signal transduction. Blood 1994;84: 3040-3046.
23. Levy Y, Labaume S, Colombel M, et al. Retinoic acid modulates the growth of IL-6 autocrine human myeloma cells via induction of apoptosis. Clin Exp Immunol 1996;104:167-172.
24. Spets H, Jernberg-Wiklund H, Sambade C, et al. The effects on growth and survival of IL-6 can be dissociated in the U-266-1970/ U-266-1984 and HL407E/HL407L human multiple myeloma cell lines. Br J hematol 1997;98:126-133.
25. Gianni M, Koken MH, Chelbi-Alix MK, et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998;91:4300-4310.
26. Shao W, Fanelli M, Ferrara FF, et al. Arsenic trioxide as an inducer of apoptosis and loss of PMI/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998;90:124-133.
27. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999; 189:1043-1052.